好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Association of Elevated Troponin Levels on Stroke Outcomes After Mechanical Thrombectomy
Cerebrovascular Disease and Interventional Neurology
S20 - Cerebrovascular Disease: Large Vessel Occlusions and Thrombectomy (3:42 PM-3:54 PM)
002

The aim of the current study was to describe troponin levels in patients with large vessel occlusion (LVO) who underwent mechanical thrombectomy (MT) and associated outcomes.

Elevated troponin levels during acute ischemic stroke have been associated with atrial fibrillation, increased National Institutes of Health Stroke Scale (NIHSS) score, embolic stroke, and cardioembolic stroke.

Data was retrospectively abstracted from a tertiary-care, comprehensive stroke center database of patients with LVO undergoing MT between February 2015 and September 2018. We compared baseline characteristics and overall outcomes of patients with normal (<0.034), mildly elevated (0.034-0.2), and critically elevated (>0.2) admission and peak troponin levels.  Multivariate logistic regression model was used to adjust for socio-demographics, admission NIHSS, and successful reperfusion defined as thrombolysis-in-cerebral-infarction 2b-3. 

Of the 348 consecutive patients identified, troponin levels were obtained in 204 (59%) patients. The mean age was 71+14 years, 47% were female, and 43% were Hispanic. The mean admission NIHSS was 16±9.0 and 53% had cardioembolic stroke. Median admission troponin was 0 (IQR 0-0.04; range 0-27.4) and peak troponin was 0.08 (IQR 0-0.66; range 0-49.4). Admission and peak troponin was >0.2 in 26/204 (13%) and 40/204 (19%) patients respectively. 21/348 (6%) were diagnosed with myocardial infarction (MI). Normal admission troponin was less likely to be associated with symptomatic hemorrhagic conversion (sICH) (OR 0.35, p 0.049). Peak troponin >0.2 was associated with higher inpatient mortality (OR 11.2, p 0.035); however, this association was not significant after excluding patients with MI (p 0.51). There was no difference in good functional outcome on discharge (modified Rankin Score 0-3).

Patients with normal troponin in the setting of LVO had lower risk of sICH after MT. Elevated peak troponin >0.2 is independently associated with in-hospital mortality; however, this association is driven primarily by patients with confirmed MI. 

Authors/Disclosures
Melissa Bailey, MD
PRESENTER
Dr. Bailey has nothing to disclose.
Vasu Saini, MD (Mount Sinai Medical Center) Dr. Saini has nothing to disclose.
Juan Sebastian Diaz, MD (University of Miami, Dept of Neurology) No disclosure on file
Sishir Mannava, MD (UT Health) Dr. Mannava has nothing to disclose.
Elizabeth Jordan No disclosure on file
Nastajjia Krementz, MD (Vascular Neurology - University of Miami/Jackson Health System) Dr. Krementz has nothing to disclose.
Mario P. Zamora Dr. Zamora has nothing to disclose.
Luis Guada-Delgado, MD (University of Miami) Dr. Guada-Delgado has nothing to disclose.
Daniel R. Kogan, MD (University of Miami/Jackson Memorial Hospital) No disclosure on file
Dileep R. Yavagal, MD, FAAN (University of Miami Miller School of Medicine) Dr. Yavagal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vascular Dynamics. Dr. Yavagal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Guidepoint. The institution of Dr. Yavagal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GLG. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Medtronic. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Cerenovus/Johnson & Johnson. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Stryker. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Poseydon. Dr. Yavagal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Athersys. Dr. Yavagal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gravity Medical Technology. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Poseydon. Dr. Yavagal has stock in Poseydon. Dr. Yavagal has stock in Galaxy Therapeutics. Dr. Yavagal has stock in Stentrode. Dr. Yavagal has stock in Gravity Medical. Dr. Yavagal has stock in Gravity Medical Technology. Dr. Yavagal has stock in Athersys. Dr. Yavagal has stock in Rapid Medical . Dr. Yavagal has received intellectual property interests from a discovery or technology relating to health care. Dr. Yavagal has received personal compensation in the range of $5,000-$9,999 for serving as a Medicolegal Expert with Royal Carribean Cruise Line. Dr. Yavagal has received personal compensation in the range of $5,000-$9,999 for serving as a Medicolegal Consultant with Carnival Cruise Line.
Nicole B. Sur, MD (University of Miami) Dr. Sur has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Stroke. The institution of Dr. Sur has received research support from Florida Stroke Registry. The institution of Dr. Sur has received research support from Miami CTSI & NIH/NINDS.